<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of earliest event reported: June 17, 1997
AUTONOMOUS TECHNOLOGIES CORPORATION
(Exact name of registrant as specified in its charter)
Florida 0-28278 59-2554729
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation) Identification No.)
2800 Discovery Drive, Orlando, Florida 32826
(Address of registrant's principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (407) 384-1600
___________________________________________________________________
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5: OTHER EVENTS
On June 17, 1997 the Company entered into agreements with accredited
investors for the purchase of 3,000,000 shares of common stock at $3.00 per
share. The Company's press release in the matter, dated June 17, 1997, entitled
"Autonomous Technologies Announces $9 Million Private Placement Through Everen
Securities" is attached as Exhibit 99.1.
EXHIBITS
Exhibit Number Exhibit Table
- -------------- -------------
99.1 Press Release entitled "Autonomous Technologies Announces $9
Million Private Placement Through Everen Securities," dated
June 17, 1997.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Autonomous Technologies Corporation
Date: June 20, 1997 By: /s/ Randy W. Frey
------------- -----------------------------------
Randy W. Frey, Chairman of the Board,
President, and Chief Executive Officer
2
<PAGE>
INDEX TO EXHIBITS
Sequentially
------------
Exhibit Description Numbered Page
- ------- ----------- -------------
99.1 Press Release entitled "Autonomous Technologies
Announces $9 Million Private Placement Through Everen
Securities," dated June 17, 1997.
3
<PAGE>
EXHIBIT 99.1
PRESS RELEASE
(BW) (AUTONOMOUS-TECHNOLOGIES) (ATCI) Autonomous Technologies
Announces $9 Million Private Placement Through Everen Securities
Business Editors & Health/Medical Writers
ORLANDO, Fla.--(BW HealthWire)--June 17, 1997--AUTONOMOUS TECHNOLOGIES
CORPORATION (NASDAQ: ATCI) today announced that it has entered into agreements
with accredited investors for the purchase of 3,000,000 shares of common stock
at $3.00 per share. The closing of the purchase is conditioned upon a resale
registration statement covering the privately placed shares being declared
effective by the Securities and Exchange Commission. The Company will file a
resale registration statement with the Securities and Exchange Commission within
the next few days. The placement agent for this offering is EVEREN Securities,
Inc.
Randy Frey, Chairman and Chief Executive Officer of Autonomous
Technologies Corporation stated, "This financing is a key component of our
growth strategy as it provides us with the resources to market our T-PRK(R)
laser system in Europe and Canada while we continue the process of obtaining FDA
approval for marketing the T-PRK laser system in the United States. With this
financing, we will have significantly broadened institutional ownership of our
stock which we believe acknowledges the strength of Autonomous' innovative
product."
The net proceeds for the offering will be used to fund the Company's
costs of clinical trials, new product development, other on-going operations,
capital expenditures and working capital. Upon closing of this private offering,
the Company will have approximately 9.9 million shares of common stock
outstanding.
ATCI is engaged in the design and development of the next generation
excimer laser instruments for laser refractive surgery. ATCI's T-PRK
(Tracker-assisted Photorefractive Keratectomy) instrument combines high speed,
laser radar eye-tracking (LADARVision(R)) with precisely controlled, narrow-beam
shaping technology.
<PAGE>
The statements in this press release indicating that the closing of this
offering will take place upon the effectiveness of a resale registration
statement are forward looking statements. The purchasers in this offering are
not required to close if the resale registration statement is not declared
effective on or before August 13, 1997 or if the representations and warranties
of the Company contained in the stock purchase agreements cease to be true and
correct. The statement concerning obtaining FDA approval is a forward looking
statement. Important factors which could cause actual results to differ from
this statement are detailed in the Company's Registration Statement dated May 1,
1996 and the Form 10-K filed with the Securities and Exchange Commission.
CONTACT: Roslyn Palmiere
Investor Relations
Autonomous Technologies
(407) 384-1603
or
INVESTOR RELATIONS CONTACT:
Evan D. Smith, CFA/Olga Fleming
[email protected]/[email protected]
Lippert Heilshorn & Associates, Inc.
(212) 838-3777
END
